Yixuan Long

Davis Polk is acting as special tax counsel to Pfizer Inc. on the combination of its off-patent branded and generic established medicines business, Upjohn, with Mylan N.V. Under the terms…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the follow-on offering of 8,050,000 shares of common stock of…

Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by International Flavors & Fragrances Inc. of $1.5 billion aggregate…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by International Flavors & Fragrances Inc. of €1.1 billion aggregate principal…

Davis Polk advised the representatives of the underwriters in connection with a $1.65 billion SEC-registered offering of 12,667,947 shares of common stock (which included 1,151,632 shares…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the approximately $125 million public offering of common stock of…

Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common stock of Coherus BioSciences, Inc. Based in Redwood City, California,…

Davis Polk advised the book-running manager on an SEC-registered offering by Mohawk Capital Finance S.A. of floating-rate notes due 2020. The notes are fully and unconditionally…

Davis Polk advised the joint book-running managers and several other underwriters in connection with SEC-registered offerings of 12,669,491 shares of common stock (which included 1,652,542…